[HTML][HTML] Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after …
K Azuma, T Hirashima, N Yamamoto, I Okamoto… - ESMO open, 2016 - Elsevier
Background Patients with epidermal growth factor receptor (EGFR) activation mutation-
positive non-small-cell lung cancer (NSCLC) respond well to EGFR tyrosine kinase …
positive non-small-cell lung cancer (NSCLC) respond well to EGFR tyrosine kinase …
Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: a retrospective …
P Cioffi, V Marotta, C Fanizza… - Journal of Oncology …, 2013 - journals.sagepub.com
Aims and background: Erlotinib approval was supported by the positive results of a large
multicentric phase III trial (BR. 21 study) that included 10% Asiatic patients and the …
multicentric phase III trial (BR. 21 study) that included 10% Asiatic patients and the …
Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non-small-cell lung cancer: A meta analysis
M Yi, T He, K Wang, Y Wei - Clinics, 2023 - SciELO Brasil
This study aimed to perform a meta-analysis comparing the efficacy and safety of gefitinib in
combination with chemotherapy versus gefitinib alone in patients with advanced Non-Small …
combination with chemotherapy versus gefitinib alone in patients with advanced Non-Small …
A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of …
Purpose Efficacy of gefitinib therapy strongly depends on epidermal growth factor receptor
(EGFR) mutation status in patients with non-small cell lung cancer (NSCLC). However …
(EGFR) mutation status in patients with non-small cell lung cancer (NSCLC). However …
A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of …
Y Matsumoto, M Maemondo, Y Ishii, K Okudera… - Lung Cancer, 2014 - Elsevier
Objectives Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are
particularly effective in non-small cell lung cancer (NSCLC) patients harboring active EGFR …
particularly effective in non-small cell lung cancer (NSCLC) patients harboring active EGFR …
[HTML][HTML] Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03
Background Gefitinib is active in patients with pretreated non-small-cell lung cancer
(NSCLC). We evaluated the activity and toxicity of gefitinib first-line treatment in advanced …
(NSCLC). We evaluated the activity and toxicity of gefitinib first-line treatment in advanced …
[HTML][HTML] A retrospective comparison of the clinical efficacy of gefitinib, erlotinib, and afatinib in Japanese patients with non-small cell lung cancer
A Fujiwara, M Yoshida, H Fujimoto, H Nakahara… - Oncology …, 2018 - ncbi.nlm.nih.gov
Tyrosine kinase inhibitors (TKIs) are very effective against non-small cell lung cancer
(NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval …
(NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval …
Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib
K Asami, M Kawahara, S Atagi, T Kawaguchi, K Okishio - Lung Cancer, 2011 - Elsevier
PURPOSE: We investigated survival potential in patients receiving erlotinib after failure of
gefitinib, focusing on response and time to progression (TTP) with gefitinib. METHODS: We …
gefitinib, focusing on response and time to progression (TTP) with gefitinib. METHODS: We …
Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating …
WS Wu, YM Chen, CM Tsai… - Experimental and …, 2012 - spandidos-publications.com
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are an effective
treatment for advanced non-small cell lung cancer. The objective of the present study was to …
treatment for advanced non-small cell lung cancer. The objective of the present study was to …
Erlotinib in non-small-cell lung cancer
C Gridelli, A Rossi, P Maione… - Expert opinion on …, 2007 - Taylor & Francis
Epidermal growth factor receptor (EGFR) plays an essential role in normal cell growth and
differentiation, and is involved in tumour proliferation and survival. EGFR overexpression is …
differentiation, and is involved in tumour proliferation and survival. EGFR overexpression is …